Comparing methods to increase liver size before surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the efficacy and safety of three different methods to increase the future remnant liver (FRL) size in patients with malignant liver lesions who are candidates for liver resection. The methods being compared are Portal Vein Embolization (PVE), Liver Vein Deprivation (LVD), and partial ALPPS (Associating Liver Partition and Portal vein Ligation for Staged hepatectomy). The study will assess both volumetric increases using computer tomography scans and functional increases through 99mTc-mebrofenin scintigraphy. This is a randomized trial, addressing a gap in previous research that primarily focused on retrospective analyses and volumetric assessments alone.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age \>= 18 years
* patients qualified for liver resection
* future remnant liver \<30% of standard liver volume
* written informed consent

Exclusion Criteria:

* liver cirrhosis
* pregnancy
* poor general health status or comorbidities excluding general anesthesia or hepatic resection
* contraindications to iodine contrast agents

Where it's running

• Second Department of Clinical Radiology
  Warsaw, Masovian Voivodeship, Poland Recruiting

Study contacts

• Principal investigator: Karolina Grąt, PhD — Medical University of Warsaw
• Study coordinator: Karolina Grąt, PhD
• Email: karolina.grat@wum.edu.pl
• Phone: +48225992300

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using AI to improve treatment for liver tumors

  This study is testing whether using artificial intelligence can help doctors choose the best treatments and predict outcomes for patients with liver tumors undergoing thermal ablation.

  Recruiting Leiden University Medical Center · Leiden · NCT06179602

• Evaluating the impact of MR-guided radiation therapy on cancer treatment outcomes

  This study is testing how using a special type of radiation therapy with real-time imaging can improve treatment results and quality of life for adults with cancer.

  Recruiting at 14 sites UMC Utrecht · Pittsburgh, Pennsylvania and 17 other locations · NCT04075305

• Predicting liver failure after major liver surgery using CT measurements and vascular shape changes

  Doctors are testing whether adding vascular deformation mapping to CT measurements can better predict liver failure after removing a large portion of the liver.

  Recruiting at 3 sites Minia University · Minya, Minya Governorate and 2 other locations · NCT07727759

• DRAGON: International registry for patients who had combined portal and hepatic vein embolization before liver surgery

  This registry collects data on patients who had PVE/HVE before liver resection to see if it helps liver regeneration and what factors relate to outcomes.

  Recruiting at 30 sites Maastricht University Medical Center · Chicago, Illinois and 30 other locations · NCT07717437

• Metastatic liver cancer patient registry from multiple Chinese centers

  This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.

  Recruiting at 2 sites Anhui Provincial Hospital · Bengbu, Anhui and 2 other locations · NCT07602504

• MRI-guided adaptive single-session radiation for liver tumors (SABR)

  This trial will test a single-session, MRI-guided adaptive high-dose radiation (SABR) for adults with primary or metastatic liver tumors to see if on-table MRI planning and replanning can treat tumors without a separate simulation visit.

  Recruiting Phase 2 Stanford University · Palo Alto, California · NCT07223307

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.